| 380.78 7.95 (2.13%) | 02-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 447.93 |
1-year : | 523.18 |
| Resists | First : | 383.5 |
Second : | 447.93 |
| Pivot price | 358.51 |
|||
| Supports | First : | 359.31 |
Second : | 344.35 |
| MAs | MA(5) : | 372.77 |
MA(20) : | 361.67 |
| MA(100) : | 365.51 |
MA(250) : | 319.56 |
|
| MACD | MACD : | 2 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 80.3 |
D(3) : | 74 |
| RSI | RSI(14): 65.1 |
|||
| 52-week | High : | 417.82 | Low : | 214.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ UTHR ] has closed below upper band by 0.8%. Bollinger Bands are 23.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 374.81 - 376.2 | 376.2 - 377.32 |
| Low: | 362.24 - 363.99 | 363.99 - 365.4 |
| Close: | 370.18 - 372.9 | 372.9 - 375.09 |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Wed, 19 Feb 2025
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Wed, 19 Feb 2025
United Therapeutics Co. (NASDAQ:UTHR) Holdings Raised by AustralianSuper Pty Ltd - MarketBeat
Sat, 15 Feb 2025
Quent Capital LLC Sells 3,232 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Thu, 13 Feb 2025
Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 101.2 (%) |
| Shares Short | 2,010 (K) |
| Shares Short P.Month | 1,920 (K) |
| EPS | 22.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 136.74 |
| Profit Margin | 40.3 % |
| Operating Margin | 54.5 % |
| Return on Assets (ttm) | 11.8 % |
| Return on Equity (ttm) | 18.8 % |
| Qtrly Rev. Growth | 22.8 % |
| Gross Profit (p.s.) | 54.88 |
| Sales Per Share | 61.82 |
| EBITDA (p.s.) | 31.58 |
| Qtrly Earnings Growth | 18.7 % |
| Operating Cash Flow | 1,140 (M) |
| Levered Free Cash Flow | 710 (M) |
| PE Ratio | 16.67 |
| PEG Ratio | 0 |
| Price to Book value | 2.77 |
| Price to Sales | 6.13 |
| Price to Cash Flow | 14.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|